[Screening for Down's syndrome in the 10th to 13th week of pregnancy].
OBJECTIVE
The implementation of antenatal screening for Down's syndrome at 10-13. week using nuchal translucency, maternal serum free subunit of human chorionic gonadotrophin and the mother's age.


METHODS
Nuchal translucency scan (NT) and serum free beta human chorionic gonadotrophin subunit (FB hCG) were measured at 283 consecutive pregnant women booked at the same antenatal care facility between 10-13. gestational week.


METHODS
Antenatal screening center Klimentska, Prague.


METHODS
Medians of both markers according to gestational age as well as retrospective combined risk of Down's syndrome were assessed.


RESULTS
95 per cent of NT measurements was below 1.77 multiples of median. 95 per cent of FB hCG measurements was below 1.88 multiples of median. Combined risk higher than 1/300 had 1 per cent mothers (total 3 screen positive results).


CONCLUSIONS
The results of this pilot study serve for implementation of screening for Down's syndrome at 10-13. week as well as for integration of both first and second trimester screening systems.
Stejskal
D
D
Oddĕlení lékarské genetiky GENNET, Poliklinika Klimentská, Praha.
Brest'ak
M
M
Hostlovská
M
M
D000328:Adult; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D004314:Down Syndrome / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008423:Maternal Age; D009333:Neck / Q000000981:diagnostic imaging; D010865:Pilot Projects; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011296:Prenatal Diagnosis; D012307:Risk Factors; D016216:Ultrasonography, Prenatal
D018997:Chorionic Gonadotropin, beta Subunit, Human